Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia

Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00180960

Enrollment

100

Registered

2005-09-16

Start date

2003-06-30

Completion date

Unknown

Last updated

2006-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appendix Tumors, Colon Tumors, Endocrine Tumors, Peritoneum Tumors, Rectum Tumors

Brief summary

The purpose of this study is to evaluate the treatment of a cancerous disease of the peritoneum with complete cytoreductive surgery with intraperitoneal chemohyperthermia using oxaliplatin plus irinotecan. This is a Phase II study with 100 patients. Origins of the tumors: these include colon, rectum, appendix, peritoneum, and endocrine tumors.

Interventions

DRUGOxaliplatin and irinotecan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Peritoneal seedings coming from colon, rectum, pseudomyxoma (appendix), peritoneum (mesothelioma and serous tumors), or endocrine tumors. * No extra-abdominal metastases * Good general status (American Society of Anesthesiologists Physical Status score \[ASA\] 1 or 2) * Signed consent

Exclusion criteria

* Tumor seedings coming from other origins * Huge peritoneal carcinomatosis (peritoneal score \> 25, except for pseudomyxomas) * Peritoneal carcinomatosis progressing rapidly * Presence of extra-abdominal metastases * Patients presenting contraindications to the use of oxaliplatin or irinotecan

Design outcomes

Primary

Measure	Time frame
To study overall survival	—

Secondary

Measure	Time frame
To study mortality-morbidity	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026